Trial Profile
Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations: A Prospective, Open-label, Cohort Study
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Brimonidine (Primary)
- Indications Port-wine stain; Vascular disorders
- Focus Therapeutic Use
- 12 Apr 2019 Status changed from recruiting to discontinued.
- 17 Apr 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 17 Apr 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Dec 2018.